Dual-specificity phosphatase 26 inhibits proliferation, migration, and invasion of prostate cancer via the TAK1-JNK/p38 signaling pathway

Author:

Huang Ruo-Hui1,Zeng Qing-Ming1,Jiang Bo1,Xu Gang1,Xiao Guan-Cheng1,Xia Wei1,Liao Yun-Feng1,Wu Yu-Ting1,Zou Jun-Rong1,Qian Biao1,Xiao Ri-Hai1,Yuan Yuan-Hu1,Zhang Guo-Xi1,Zou Xiao-Feng1

Affiliation:

1. First Affiliated Hospital of Gannan Medical University

Abstract

Abstract As the most frequently identified malignant tumor of the male genitourinary system, prostate cancer (PCa) is threatening the health of millions of people worldwide because of its malignant, easy-to-transfer, and complicated complications. Moreover, the complex pathological mechanism of prostate cancer has not been fully elaborated and needs to be further explored. Here, we found that the expression of DUSP26, a deubiquitylation enzyme, is dramatically suppressed, and a positive connection of its expression with PCa prognosis was also observed. In vitro, overexpression of DUSP26 significantly inhibited the proliferative, migrative, and invasive capacities of PC3 cell, DUSP26 silencing presented opposite results. Further tumor formation experiments in subcutaneous nude mice demonstrated that DUSP26 overexpression could significantly suppress PC3 growth in vivo. Moreover, it also suggested that the DUSP26 overexpression negatively connected to key tumorigenesis signaling pathways through analysis of RNA-Seq. Mechanically, DUSP26 significantly inhibited MAPK signaling pathway activation, and further experiments displayed that DUSP26 could impair TAK1, p38, and JNK phosphorylation. Interestingly, treatment with the TAK1 inhibitor attenuated the effect of DUSP26 on PC3 cells. Together, these results suggested that DUSP26 may serve as a novel therapeutic target for PC3 cell type PCa by inhibiting the TAK1-JNK/p38 signaling.

Publisher

Research Square Platform LLC

Reference53 articles.

1. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium;Olumi AF;CANCER RES,1999

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung H;CA-CANCER J CLIN,2021

3. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study;Hansen AR;ANN ONCOL,2018

4. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis;Serpa NA;PROSTATE CANCER P D,2012

5. Treatment of Advanced Prostate Cancer;Teo MY;ANNU REV MED,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3